{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T10:16:01Z","timestamp":1783332961241,"version":"3.54.6"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T00:00:00Z","timestamp":1781654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40259-026-00788-8","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:37:07Z","timestamp":1781692627000},"page":"599-606","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Overview and Trend Analysis of Biosimilar Approvals in China"],"prefix":"10.1007","volume":"40","author":[{"given":"Mei","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,17]]},"reference":[{"issue":"5","key":"788_CR1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40290-025-00578-7","volume":"39","author":"S Sinha","year":"2025","unstructured":"Sinha S, Raphael R. Developing biosimilars: challenges and opportunities. Pharmac Med. 2025;39(5):341\u201352. https:\/\/doi.org\/10.1007\/s40290-025-00578-7.","journal-title":"Pharmac Med"},{"issue":"10","key":"788_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.37348","volume":"6","author":"X Luo","year":"2023","unstructured":"Luo X, Du X, Li Z, et al. Clinical benefit, price, and uptake for cancer biosimilars vs reference drugs in China: A systematic review and meta-analysis. JAMA Netw Open. 2023;6(10):e2337348. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.37348.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"788_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1208\/s12249-025-03038-2","volume":"26","author":"A Monga","year":"2025","unstructured":"Monga A, Gagan A, Jamwal P, Sharma S, Kaur A. Biosimilars: a critical review of development, regulatory landscape, and clinical implications. AAPS PharmSciTech. 2025;26(1):46. https:\/\/doi.org\/10.1208\/s12249-025-03038-2.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"788_CR4","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s40267-025-01145-5","volume":"41","author":"MC Raposo","year":"2025","unstructured":"Raposo MC, Feiteira C, Ribeiro MHL. Regulatory and clinical aspects in biosimilar medicines: comparability, extrapolation, interchangeability, and safety. Drugs Therapy Perspect. 2025;41(3):111\u201325. https:\/\/doi.org\/10.1007\/s40267-025-01145-5.","journal-title":"Drugs Therapy Perspect"},{"key":"788_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/978-3-031-30023-3_11","volume-title":"Pharmaceutical biotechnology: fundamentals and applications","author":"AG Vulto","year":"2024","unstructured":"Vulto AG, Barbier L. Biosimilars: principles, regulatory framework, and societal aspects. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology: fundamentals and applications. Springer International Publishing; 2024. p. 267\u201381."},{"key":"788_CR6","unstructured":"China National Medical Products Administration. Guiding Principles for the Research and Evaluation of Biosimilars (Trial Version). Accessed Jan 15, 2026. https:\/\/www.cde.org.cn\/zdyz\/downloadAtt?idCODE=5097ae71b10504a18ef6c90c7a6969ab"},{"key":"788_CR7","doi-asserted-by":"publisher","unstructured":"Hong XSZ, Ma S, Lan F, Shu R. Brief introduction on the development of Chinese Pharmacopoeia 2025 Edition. Drug Standards of China 2025;26(1):1-10. https:\/\/doi.org\/10.19778\/j.chp.2025.01.001","DOI":"10.19778\/j.chp.2025.01.001"},{"key":"788_CR8","unstructured":"European Medicines Agency. Human medicines in 2025. Accessed Jan 27, 2026. https:\/\/www.ema.europa.eu\/en\/about-us\/what-we-do\/authorisation-medicines\/medicine-evaluation-figures"},{"key":"788_CR9","unstructured":"U.S. Food and Drug Administration. Biosimilar Product Information. Accessed Jan 15, 2026. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information"},{"key":"788_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1476213","author":"X Du","year":"2024","unstructured":"Du X, Luo XX, Guo QX, et al. Assessment of clinical benefit, cost and uptake of biosimilars versus reference biologics in immune-mediated inflammatory diseases in China. Front Public Health. 2024. https:\/\/doi.org\/10.3389\/fpubh.2024.1476213.","journal-title":"Front Public Health"},{"key":"788_CR11","unstructured":"National Medical Products Administration. Registration Classification and Application Information Requirements for Biological Products Accessed Jan 15, 2026. https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/images\/uL28qO6ICDJ+s7v1sbGt9eisuG31sDgvLDJ6rGo18rBz9KqxMuZG9j.doc"},{"key":"788_CR12","unstructured":"National Medical Products Administration. Biosimilars Guidances. Accessed Mar 31, 2026. https:\/\/www.cde.org.cn\/main\/fullsearch\/fullsearchpage"},{"key":"788_CR13","unstructured":"European Medicines Agency. Scientific Guidelines on Biosimilar Medicinal Products Accessed Mar 31, 2026. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/scientific-guidelines\/multidisciplinary-guidelines\/multidisciplinary-biosimilar"},{"key":"788_CR14","unstructured":"U.S. Food and Drug Administration. Biosimilars Guidances. Accessed Mar 31, 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/general-biologics-guidances\/biosimilars-guidances"},{"issue":"6","key":"788_CR15","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1080\/14712598.2025.2507832","volume":"25","author":"E Car","year":"2025","unstructured":"Car E, Barbier L, Huys I, et al. Evolving global regulatory landscape for approval of biosimilars: current challenges and opportunities for convergence. Expert Opin Biol Ther. 2025;25(6):649\u201368. https:\/\/doi.org\/10.1080\/14712598.2025.2507832.","journal-title":"Expert Opin Biol Ther"},{"key":"788_CR16","unstructured":"National Medical Products Administration. Questions and Answers on Similarity Studies of Biosimilars. Accessed Jan 15, 2026. https:\/\/www.cde.org.cn\/main\/att\/download\/02af6f87ccee0ff56a8231ca6704ee9b"},{"key":"788_CR17","unstructured":"Center for Drug Evaluation. Technical Review Report for Marketing Authorization Application of Infliximab for Injection (JXSS2100022). Accessed May 13, 2026. https:\/\/www.cde.org.cn\/main\/xxgk\/postmarketpage?acceptidCODE=3ac1c50f3cccc90b4a0e688fad8304dd"},{"key":"788_CR18","doi-asserted-by":"publisher","unstructured":"Hu YY, Cheng SY. General considerations for the development and similarity evaluation of dulaglutide biosimilars.\u00a0Chin J New Drugs. 2025;34(24):2639\u201345.\u00a0https:\/\/doi.org\/10.20251\/j.cnki.1003-3734.2025.24.011","DOI":"10.20251\/j.cnki.1003-3734.2025.24.011"},{"issue":"4","key":"788_CR19","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40268-020-00321-4","volume":"20","author":"SJ Schrieber","year":"2020","unstructured":"Schrieber SJ, Putnam WS, Chow ECY, et al. Comparability considerations and challenges for expedited development programs for biological products. Drugs R D. 2020;20(4):301\u20136. https:\/\/doi.org\/10.1007\/s40268-020-00321-4.","journal-title":"Drugs R D"},{"issue":"18","key":"788_CR20","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.3748\/wjg.v29.i18.2733","volume":"29","author":"RF Souza","year":"2023","unstructured":"Souza RF, Caetano MAF, Magalh\u00e3es HIR, et al. Study of tumor necrosis factor receptor in the inflammatory bowel disease. World J Gastroenterol. 2023;29(18):2733\u201346. https:\/\/doi.org\/10.3748\/wjg.v29.i18.2733.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"788_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, Ranibizumab and Bevacizumab. Angiogenesis. 2012;15(2):171\u201385. https:\/\/doi.org\/10.1007\/s10456-011-9249-6.","journal-title":"Angiogenesis"},{"issue":"1","key":"788_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-013-0252-z","volume":"17","author":"N Boku","year":"2014","unstructured":"Boku N. HER2-positive gastric cancer. Gastric Cancer. 2014;17(1):1\u201312. https:\/\/doi.org\/10.1007\/s10120-013-0252-z.","journal-title":"Gastric Cancer"},{"issue":"3","key":"788_CR23","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/dom.16110","volume":"27","author":"J Wen","year":"2025","unstructured":"Wen J, Razick A, How-Volkman C, et al. An exploratory analysis of glucagon-like peptide-1 (GLP-1) agonists and biosimilars: a literature review. Diabetes Obes Metab. 2025;27(3):1113\u201322. https:\/\/doi.org\/10.1111\/dom.16110.","journal-title":"Diabetes Obes Metab"},{"key":"788_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2024.101744","volume":"85","author":"G Xu","year":"2024","unstructured":"Xu G, Wang J. The current status of the biosimilars landscape in China. Biologicals. 2024;85:101744. https:\/\/doi.org\/10.1016\/j.biologicals.2024.101744.","journal-title":"Biologicals"},{"issue":"1","key":"788_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","volume":"131","author":"N van de Donk","year":"2018","unstructured":"van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2018;131(1):13\u201329. https:\/\/doi.org\/10.1182\/blood-2017-06-740944.","journal-title":"Blood"},{"key":"788_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke WH. The IL-17 family of cytokines in Psoriasis: IL-17A and beyond. Front Immunol. 2018;9:1682. https:\/\/doi.org\/10.3389\/fimmu.2018.01682.","journal-title":"Front Immunol"},{"issue":"1","key":"788_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of Dupilumab. Clin Exp Allergy. 2020;50(1):5\u201314. https:\/\/doi.org\/10.1111\/cea.13491.","journal-title":"Clin Exp Allergy"},{"issue":"1","key":"788_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-025-10304-w","volume":"52","author":"ZS Aghili","year":"2025","unstructured":"Aghili ZS, Khoshnevisan G, Mostoli R, et al. Growth hormone signaling and clinical implications: from molecular to therapeutic perspectives. Mol Biol Rep. 2025;52(1):202. https:\/\/doi.org\/10.1007\/s11033-025-10304-w.","journal-title":"Mol Biol Rep"},{"key":"788_CR29","unstructured":"Medpath. Pharmaceutical Industry Braces for $236 Billion Patent Cliff by 2030: Strategic Responses from Major Players. Accessed Jan 15, 2026. https:\/\/trial.medpath.com\/news\/bdeaa1ba345678a3\/pharmaceutical-industry-braces-for-236-billion-patent-cliff-by-2030-strategic-responses-from-major-players"},{"key":"788_CR30","unstructured":"European Medicines Agency. Reflection paper on a tailored clinical approach in biosimilar development. Accessed May 6, 2026. https:\/\/www.ema.europa.eu\/en\/documents\/other\/reflection-paper-tailored-clinical-approach-biosimilar-development_en.pdf-0"},{"key":"788_CR31","unstructured":"U.S. Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies. Accessed Jan 15, 2026. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/scientific-considerations-demonstrating-biosimilarity-reference-product-updated-recommendations"},{"key":"788_CR32","unstructured":"ICH. M18: Framework for Determining the Utility of Comparative Efficacy Studies in Biosimilar Development Programs November 2025. Accessed Jan 15, 2026. https:\/\/database.ich.org\/sites\/default\/files\/ICH_M18_Final_Concept_Paper_MCEndorsed_2025_1119.pdf"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-026-00788-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-026-00788-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:38:45Z","timestamp":1783330725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-026-00788-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,17]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["788"],"URL":"https:\/\/doi.org\/10.1007\/s40259-026-00788-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,17]]},"assertion":[{"value":"25 May 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"The data analyzed in this study were compiled based on publicly available resources, including official documents and publicly accessible information from the National Medical Products Administration (NMPA) and the Center for Drug Evaluation (CDE) of China, as well as commercial databases. All relevant data are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study and met the requirements for authorship and submissions. NZ and MY developed the concept for this article. MY took part in data collection and analysis, and wrote the first manuscript. NZ and HXW made critical revisions to the draft. All authors critically reviewed and approved the final manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}